Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zika virus immune globulin
- Development stage
- Phase 1
- Lead developer
- Emergent BioSolutions
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
Zika virus immune globulin (ZIKV-Ig) is a purified human immunoglobulin product containing polyclonal antibodies that neutralize the Zika virus. It is derived from pooled plasma of healthy adult donors with elevated levels of anti-Zika antibodies and manufactured using a hyperimmune platform process. The primary indication for ZIKV-Ig is prophylaxis against Zika virus infection in at-risk populations, including women of childbearing potential and pregnant women. The drug acts by providing passive immunity through its content of neutralizing IgG antibodies targeting the Zika virus[1][4][5]. Emergent BioSolutions developed this investigational biologic, which has undergone phase 1 clinical trials to assess safety and pharmacokinetics[6]. The mechanism involves direct viral neutralization via polyclonal antibody binding.
- Other names
- human anti-Zika virus immunoglobulinanti-Zika virus immune globulin
02
Targets
ZIKV E (Zika virus envelope protein)
Beyond the preview
Go deeper on Zika virus immune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zika virus immune globulin.